Company Filing History:
Years Active: 2024
Title: Innovations by David M Evans
Introduction
David M Evans is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of therapeutic compounds, particularly in the area of nucleic acid delivery. With a total of 2 patents to his name, Evans is recognized for his innovative approaches to addressing critical health challenges.
Latest Patents
One of his latest patents is titled "Peptide docking vehicle for targeted nucleic acid delivery." This patent describes peptide docking vehicle compositions that contain a therapeutic compound, such as an siRNA molecule, and a targeting ligand. The methods outlined in this patent allow for targeted delivery of the therapeutic compound to specific cells or tissues, enhancing the therapeutic benefit for both animals and humans.
Another significant patent is "Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV)." This patent provides compositions and methods for developing potent siRNA therapeutics aimed at preventing and treating COVID-19 infections. The compositions include pharmaceutical formulations comprising siRNA cocktails that target critical viral genes, along with polymeric and liposomal nanoparticle carriers. Various administration methods, such as airway instillation and nebulizer aerosolization, are also detailed.
Career Highlights
David M Evans is currently associated with Sirnaomics, Inc., where he continues to work on groundbreaking innovations in the field of RNA therapeutics. His expertise and dedication to research have positioned him as a key figure in the development of novel therapeutic strategies.
Collaborations
Evans collaborates with notable colleagues, including Patrick Y Lu and Danny Tang. Their combined efforts contribute to advancing the field of therapeutic innovations.
Conclusion
David M Evans is a distinguished inventor whose work in targeted nucleic acid delivery and RNA therapeutics has the potential to significantly impact public health. His patents reflect a commitment to developing innovative solutions for pressing medical challenges.